Icecure Medical Ltd. (ICCM)
NASDAQ:ICCM
Want to see ICCM full AI Analyst Report?
Earnings Data
Report Date
Aug 17, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.05Last Year’s EPS
-0.06Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveys strong positive momentum driven by 26% revenue growth, outsized North America (84%) and U.S. (31%) gains, FDA clearance, increasing active accounts (+46%), an approved 30‑site Choice post‑market study, and expanding commercial and clinical validation. Key near‑term risks include reimbursement timing (CPT‑1 and pass‑through uncertainty), limitations for office‑based reimbursement, and multi‑quarter conversion timelines for leads to system sales. On balance, the positives (regulatory milestone, accelerating sales, study approval and pipeline growth) outweigh the challenges, while some execution and reimbursement risks remain.Company Guidance
Quarterly Revenue Growth
Reported revenue growth of 26% year-over-year for Q1 2026, driven by new system placements and increased sales of disposable probes.
Strong North America and U.S. Performance
North America sales increased 84% and U.S. sales grew 31% in Q1, reflecting accelerating commercial momentum after FDA clearance.
Increase in Active U.S. Accounts
Active U.S. account base rose from 13 to 19 following FDA approval, a 46% increase compared to the pre‑approval active account level.
FDA Clearance and Global Impact
FDA clearance for low‑risk early breast cancer secured (key validation milestone); clearance is driving higher international interest across Europe, Asia and the Americas and stronger physician engagement at major conferences.
Choice Post‑Market Study Approval
Choice post‑market study received FDA approval in Q1 and will include 30 clinical/commercial hybrid U.S. sites (about half of current active sites intend to participate), expected to accelerate adoption and generate additional clinical data.
Reimbursement Progress
Procedures already supported by an established CPT facility code covering about $4,000; company plans to submit for a CPT‑1 physician reimbursement code in June (decision expected early 2027) and has applied for transitional pass‑through payment that could add roughly $9,000 if qualified.
Commercial Scale-Up Plans
Company is expanding its U.S. commercial organization (hiring sales reps) to increase footprint; strong lead generation at recent conferences and a robust pipeline provide visibility into further system sales and installations across 2026 and into early 2027.
Clinical Validation and Physician Support
Growing independent clinical research and investigator‑initiated studies (including ICE3 data) plus the 2026 American Society of Breast Surgeons resource guide recommending cryoablation for select low‑risk patients reinforce clinical acceptance; investigator feedback (Dr. Fine) reports encouraging outcomes and high physician interest.
Regulatory Progress in Other Markets
Engagement with Health Canada (amendment submitted in March; company expects a decision prior to year‑end) and active progress toward PMDA submission in Japan via partner, indicating parallel international expansion efforts.
ICCM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ICCM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $0.24 | $0.24 | 0.00% |
Mar 17, 2026 | $0.73 | $0.67 | -8.90% |
Nov 19, 2025 | $0.72 | $0.70 | -2.78% |
Aug 13, 2025 | $0.82 | $0.84 | +2.44% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Icecure Medical Ltd. (ICCM) report earnings?
Icecure Medical Ltd. (ICCM) is schdueled to report earning on Aug 17, 2026, Before Open (Confirmed).
What is Icecure Medical Ltd. (ICCM) earnings time?
Icecure Medical Ltd. (ICCM) earnings time is at Aug 17, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ICCM EPS forecast?
ICCM EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.